Scarica l'app Stockscreener
10.16
1.09%
0.11
Dopo l'orario di chiusura:
10.25
0.09
+0.89%
Precedente Chiudi:
$10.05
Aprire:
$10.33
Volume 24 ore:
17,028
Relative Volume:
0.50
Capitalizzazione di mercato:
$91.11M
Reddito:
-
Utile/perdita netta:
$-40.62M
Rapporto P/E:
-0.5235
EPS:
-19.4076
Flusso di cassa netto:
$-35.63M
1 W Prestazione:
+4.26%
1M Prestazione:
-2.21%
6M Prestazione:
+8.78%
1 anno Prestazione:
-20.78%
Intervallo 1D:
$10.06
$10.73
Intervallo di 1 settimana:
$9.0901
$10.75
Portata 52W:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Nome
Promis Neurosciences Inc
Settore
Industria
Telefono
416-847-6898
Indirizzo
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
10.16 | 90.13M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Promis Neurosciences Inc Borsa (PMN) Ultime notizie
ProMIS Neurosciences (PMN) Dips 3.54% as Biotech Stock Tests Key Support ZonePrice Action Signals - newsline.com
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy - Yahoo Finance
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet - Yahoo Finance
ProMIS Neurosciences Inc. (PMN) Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pipeline AdvancesAnalyst Drop Coverage - newsline.com
H.C. Wainwright reiterates Buy on ProMIS Neurosciences stock By Investing.com - Investing.com Canada
PMN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
PMN Q1 2026 Earnings: Narrower-than-Expected Loss Amid Ongoing Clinical DevelopmentROA Comparison - newsline.com
ProMIS Neurosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
PMN Q1 2026 Earnings: EPS Surprises to the Upside Despite Lack of RevenueMargin Guidance - newsline.com
ProMIS Neurosciences (PMN) Slips 3.3% as Biotech Sentiment Shifts – Key Support Holds at $9.56Median Line - newsline.com
ProMIS Neurosciences (PMN) Faces Bearish Pressure as Shares Slide 3.70%Value Stock Ideas - newsline.com
PMN Technical Analysis | Trend, Signals & Chart Patterns | PROMIS NEUROSCIENCES INC (NASDAQ:PMN) - ChartMill
ProMIS Neurosciences to Participate in Upcoming Conferences in June - The Manila Times
Alzheimer’s drug trial data from ProMIS expected in early Q3 2026 - Stock Titan
ProMIS Neurosciences (PMN) Gains Momentum as Shares Test Key Resistance Near $11.29Moving Average Crossovers - newsline.com
ProMIS Neurosciences (PMN) Slips 5.65% as Shares Test Key Support LevelWave Alternation - newsline.com
PMN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Neurodegenerative PipelineRevenue Breakdown Analysis - The Legal Advocate
PMN Q1 2026 Earnings: Narrower-than-expected Loss; Stock Gains on Pipeline ProgressPretax Income Report - Newser
Yu Fan's ProMIS Neurosciences Inc(PMN) Holding History - GuruFocus
ProMIS Neurosciences (PMN) director granted 16,500 options at $10.77 strike price - Stock Titan
ProMIS Neurosciences (PMN) director granted options on 16,500 shares - Stock Titan
ProMIS Neurosciences (PMN) CEO awarded 160,000 options at $10.77 strike - Stock Titan
ProMIS Neurosciences (PMN) director awarded long-dated stock options - Stock Titan
ProMIS Neurosciences (PMN) awards CSO 50,000 options vesting over 4 years - Stock Titan
Executive at ProMIS (PMN) receives 18,167 stock options expiring 2036 - Stock Titan
ProMIS Neurosciences (PMN) director receives 16,500 stock options grant - Stock Titan
ProMIS Neurosciences (PMN) CDO awarded 50,000 stock options - Stock Titan
Director at ProMIS Neurosciences (PMN) receives new option grants as board compensation - Stock Titan
PMN Q1 2026 Earnings: Narrowed EPS Surprise Drives Positive Stock ReactionDividend Earnings Report - The Legal Advocate
ProMIS Neurosciences (NASDAQ: PMN) shareholders approve larger 2025 stock option plan - Stock Titan
Analysts’ Top Healthcare Picks: ProMIS Neurosciences (PMN), Evolent Health (EVH) - The Globe and Mail
Great Point, Dr. Jay and Nordahl report 9.99% stake in PROMIS (PMN) - Stock Titan
Wellington Group discloses 895,871-share holding in ProMIS (PMN) - Stock Titan
ProMIS Neurosciences Inc. Q1 2026 Financial Results, Forward-Looking Statements, and Risk Factors Overview - Minichart
TradingKey - TradingKey
ProMIS Neurosciences Releases Q1 2026 Financial Results - AlphaStreet
ProMIS Neurosciences Reports Q1 2026 Results, Advances Alzheimer’s PMN310 Trial and Secures $175M Financing - Minichart
ProMIS Neurosciences (PMN) Q1 2026 Earnings: EPS N/A, Revenue N/ - GuruFocus
ProMIS (PMN) Targets Alzheimer's Treatment with Promising Trial and Funding - GuruFocus
ProMIS Neurosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ProMIS Neurosciences Inc. Q1 2026: Net income $(8.24M), Diluted EPS $(1.26) — 10-Q Summary - TradingView
ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] ProMIS Neurosciences Inc. Quarterly Earnings Report - Stock Titan
ProMIS Neurosciences (Nasdaq: PMN) boosts cash with $175M financing and advances PMN310 - Stock Titan
ProMIS Neurosciences Inc. Closes PIPE Financing of Up to $175 Million to Support Alzheimer's Disease Clinical Trial - Quiver Quantitative
Alzheimer's trial fully enrolled as ProMIS funds work through 2027 - Stock Titan
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights - ChartMill
ProMIS Neurosciences (PMN) owners report 181,632 shares (2.0%) in 13G/A amendment - Stock Titan
Insider Purchase: Director at $PMN Buys 4,000 Shares - Moomoo
ProMIS Neurosciences to execute 1-for-25 reverse stock split - MSN
Promis Neurosciences Inc Azioni (PMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Promis Neurosciences Inc Azioni (PMN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Williams Eugene | Director |
Mar 05 '26 |
Buy |
24.40 |
2,000 |
48,800 |
12,397 |
| Williams Eugene | Director |
Mar 04 '26 |
Buy |
24.00 |
2,000 |
48,000 |
10,397 |
| Williams Eugene | Director |
Mar 02 '26 |
Buy |
22.53 |
1,000 |
22,530 |
7,397 |
| Williams Eugene | Director |
Mar 03 '26 |
Buy |
21.89 |
1,000 |
21,890 |
8,397 |
| Kaplan Johanne | Chief Development Officer |
Feb 19 '26 |
Buy |
15.35 |
1,629 |
25,005 |
3,941 |
| ABG Management Ltd. | 10% Owner |
Feb 03 '26 |
Buy |
12.13 |
700,741 |
8,499,988 |
943,090 |
| Milbury Max A. | Principal Accounting Officer |
Oct 03 '25 |
Buy |
0.49 |
30,392 |
14,929 |
45,389 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):